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Stress proteins have recently been shown to be implicated in a variety of diseases,
such as nonviral infections (1) and certain autoimmune diseases (2). In particular,
ubiquitin, a heat shock protein of 76 amino acid residues found in every eukaryotic
cell, has been found to be a major antigenic target in SLE (3). There is also evidence
that the ubiquitin system is involved in diseases of the nervous system, such as Alz-
heimer and Parkinson diseases (4), and that heat shock proteins may play a central
role in all cases of inflammation where heat is a major clinical sign (5) .
The precise way in which ubiquitin is involved in these various diseases has not
yet been clarified. It is well known that ubiquitin may be present in cells both as
a free molecule and conjugated to a number of nuclear, cytoplasmic, andmembrane
acceptor proteins (6-8), and that it may also be associated to the microtubule net-
work (9) .
Cytosolic ubiquitin conjugates are known to be involved in mediating selective
degradation ofdamagedor abnormal proteins (10) . The role ofubiquitin conjugates
involving thehistones H2A andH2B remains poorly understood . Histone ubiquiti-
nation is a selective, reversible post-synthetic modification that occurs mainly in ac-
tively transcribed regionsofchromatin (11, 12) and may be involved in mechanisms
of chromatin relaxation . Ubiquitin may also indirectly modulate chromatin struc-
ture through stimulation, of histone deacetylase activity (13) . Compared with cyto-
solic conjugates, histone-ubiquitin conjugates are more slowly degraded (14) .
In the nucleus, ubiquitin was found to be enzymatically conjugated via an isopep-
tide bond between its COOH-terminal glycine 76 (a-COOH group) and the e-NH2
groups oflysine 119ofH2A and lysine 120 ofH2B, respectively, thus formingbranched
molecules (15, 16). In mammalian cells, ubiquitinated H2A (U-MA) and H2B
(U-H2B) are usually present at levels of 10% and 1%, respectively (17, 18) ; levels
of U-H2B exceed that of U-112A within "active" HI-depleted regions of chromatin
(19) . In Physarum, -6% of histones H2A and H2B are ubiquitinated (20) .
In aprevious report (3), we described the presence in SLE of autoantibodies able
to react in an ELISA with ubiquitin and with a synthetic fragment corresponding
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to residues 22-45 of the molecule. In addition, the SLE sera also reacted in immu-
noblotting with two polypeptides of Mr -52,000 and -43,000, found to be present
as contaminants in a commercial preparation of ubiquitin. Using antisera specific
for H2A and H2B, we demonstrated that these P43 and P52 components correspond
to ubiquitinated complexes containing H2A and H2A-H2B, respectively. To further
characterize these complexes, we prepared antisera against two synthetic peptides
corresponding to the branched moiety of U-1-12A and used them in immunoblotting
experiments. The results reported here confirm the presence of covalent U-1-12A
in polypeptides P43 and P52. The fine specificity of autoantibodies was defined using
the branched peptides ofU-1-12A as antigens . Close to 95 'Yo of SLE sera able to react
with ubiquitin were found to also contain antibodies specific for the branched pep-
tide of U-1-12A, suggesting that this latter conjugate may play a role in the appear-
ance of autoantibodies in SLE .
Materials and Methods
Histone Fractions and Ubiquitin.
￿
Chicken histones H2A and H2B were extracted and purified
by the acid method ofJohns (21). Ubiquitin was a commercial preparation from Sigma Chem-
ical Co., St. Louis, MO (U 6253, batch 106F-9355).
Synthetic Peptides.
￿
Synthetic peptides 22-45 and CYS 22-45 of ubiquitin have been previ-
ously described (3). Two synthetic peptides, TI and T2, corresponding to the branched re-
gion of U-H2A were prepared by classical solid-phase methods using terbutyloxycarbonyl
(Boc) for N-tx protection. The synthesis was performed on a manual system starting from
Boc-Glu (OcHx) Pam resin prepared as described elsewhere (22). For trifunctional amino
acids, the following side chain protecting groups were used: cyclohexyl for Glu, benzyl for
Thr, 2-chlorobenzyloxycarbonyl for Lys 118, Tosyl for Arg, paramethylbenzyl for Cys, 2,6-
dichlorobenzyl for Tyr, and fluorenylmethyloxycarbonyl (Fmoc)' for Lys 119 (Fig. 1).
The Boc groups were removed using 65% trifluoracetic acid in dichloromethane for 13
min. Coupling reactions were performed in dimethylformamide (DMF) with a threefold excess
ofhydroxybenzotriazol active ester prepared just before use. All amino acids gave a negative
ninhydrin test after 15 min ofcoupling. The peptides corresponding to fragment 116-121 (TI)
and 118-121 (T2) were synthesized at first; after deprotection of the last residues (Leu for
TI and Cys for T2) acetylation was performed using 10 molar excess of acetic anhydride
in the presence of the same amount of diisopropylethylamine for 10 min. The Fmoc group
ofLys 119 was deprotected by two treatments of50% piperidine in DMF (2 min each). Residues
73-76 of ubiquitin were then assembled to the Lys 119 as described above. Cleavage of the
peptide from the solid support was achieved using hydrogen fluoride in the presence of 10%
(vol/vol) of p-cresol as scavenger for 45 min at 0°C (in the case of peptide T2, 1% of 1,2-
ethanedithiol was added). The crude product was then lyophilized and purified by medium
pressure liquid chromatography. The purified products were assessed by HPLC, amino acid
analysis (6 N HCl, 110°C, 20 h), and fast atom bombardment (FAB) mass spectrometry mea-
surements.
An additional tyrosine residue was added at the NH2-terminal Leu-73 of TI and T2 to
allow the peptide to be conjugated to carrier protein by means of bis-diazotized benzidine
(23). Before conjugation, internal lysines of peptides were protected by citraconylation. The
yield of coupling was checked by amino acid composition. An N1-12-terminal cysteine res-
idue was added in the case of peptide T2 in order to allow subsequent coupling ofthe peptide
through its SH group.
Rabbit Antisera to Histones, Ubiquitin, Synthetic Peptides, and Human Sera.
￿
Antisera to purified
histones H2A, H2B, H3, and H4 were those used in previous works (24-27). Antiubiquitin
antiserum and antisera to peptides 22-45 and CYS 22-45 were raised in rabbits as previously
1 Abbreviations used in this paper.. DMF, dimethylformamide; FAB, fast atom bombardment; Fmoc,
fluorenylmethyloxycarbonyl; RA, rheumatoid arthritis.described (3) . Antisera to peptides TI and T2 were obtained by immunizing rabbits (two
animals for each peptide) by means of eight intramuscular injections of 50 p,g (expressed
in peptide) ofOVA-conjugated peptide (molar ratio carrier/peptide, 1 :14 and 1:16, respec-
tively, for Tl and T2). For the first injection, the conjugated peptide was emulsified with
an equal volume of CFA and for the subsequent injections with IFA. Rabbits were bled 1
wk after each injection from the third. Human sera from patients with SLE and related au-
toimmune diseases were those used previously (3).
Immunological Tests.
￿
The ELISA used to measure the binding of rabbit and human anti-
bodies towards histones and ubiquitin was described previously (3, 27). Respectively, 200
ng/ml H2A and 500 ng/ml ubiquitin were used for coating microtiter plates. The antigenic
activity of peptides T1 and T2 was measured in microtiter plates directly coated with 2 /AM
peptide in 0.05 M carbonate buffer, pH 9 .6. Immunoblotting experiments were performed
as described previously (3), after separation of polypeptides by SDS 12-20% PAGE.
Affinity Chromatography.
￿
Peptide T2 was coupled either through its SH group to activated
thiol Sepharose 4B as described by the supplier (Pharmacia Fine Chemicals, Piscataway, NJ)
or through its amino groups to Act-Ultrogel AcA 22 (IBF, Villeneuve La Garenne, France)
preactivated with glutaraldehyde. 500 Ftl of rabbit T2 antiserum or 200-500 JA of SLE serum
was allowed to react with peptide adsorbant equilibrated in 10 mM PBS, pH 7.5. After 3 h
incubation at room temperature, the flow-through was collected for characterization. The
peptide-adsorbant column was extensively washed with 10 mM PBS, pH 7 .5, and antibody
was eluted from the column with 0.2 M glycine, pH 3.0. The fractions (0.5 ml) were immedi-
ately neutralized with 0.1 M Tris, pH 8.8 (vol/vol). The eluted fractions were characterized
by ELISA.
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Results
Branched Synthetic Peptides TI and T2.
￿
The sequence of the two peptides, T1 and
T2, is shown in Materials and Methods. The classical solid phase methodology used
for the synthesis of the two peptides gave excellent results since both crude peptides
T1 and T2 had a purity >70% . In this case, the Fmoc group was ideally suited for
the side chain protection of Lys and this approach seems to be well adapted to the
synthesis of branched peptides. The final products used in the immunochemical studies
had a purity of 95% (see Fig. 2 for HPLC analysis). Amino acid analysis of the
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FIGURE 2.
￿
HPLC profile of purified
peptides TI andT2. Thepeptideswere
_,
￿
detected by UVabsorbance at 210 nm.
50
￿
A 4.6 x 250-mm aquapore RP 300 Cs
column was used. Mobile phase A was
triethylamine phosphate buffer, pH
2 .5, and mobile phase B was acetoni-
trile. Elution was performed with a
linear gradient of 1-21% over 21 min
at a flow rate of 2 ml/min.1610
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peptides gave the following composition (expected values indicated in parentheses):
for peptide TI: Glx 1.00 (1), Gly 2.00 (2), Arg 0.95 (1), Thr 1.15 (1), Pro 0.95 (1),
Tyr 1.02 (1), Leu 1.82 (2) Lys 2.11 (2); for peptide T2: Glx 1.01 (1), Gly 1.97 (2),
Arg 0.97 (1), Thr 1.08 (1), Tyr 1.03 (1), Cys0.87 (1), Leu 1.06 (1), Lys 1.87 (2). Molec-
ular weights ofthe peptides were confirmed by FAB mass spectrometry, which gave
the following values for the quasi molecular ion MH+ (calculated values are given
in parentheses): for Tl, 1,303.8 (1,303 .5); for T2, 1,196.6 (1,196.6).
The stability oflyophilizedpeptides T1 andT2 was controlled by HPLC analysis.
After several months of storage at room temperature in the dark, no degradation
was observed; dimerization ofthe T2 peptide by its terminal cysteinewas<9 170. The
percentage ofdimerizedT2 fractiondidnot change when the peptidewas incubated
overnight in the carbonate buffer used for coatingplates in ELISA, or in bidistilled
water.
Reactivity ofAntisera to Peptides TIand T2in ELISA.
￿
Antibodies were raised against
OVA-conjugatedpeptides TI andT2. Their reactivity was measured inELISA using
plates coated with either homologous nonconjugated peptides, ubiquitin, or H2A.
A high antipeptide immune response was observed in the four immunized rabbits
after three injections ofconjugates. None ofthe antisera from the four rabbits was
able to react with ubiquitin immobilized on the solid phase. Antisera to peptide T1
obtained from both immunized rabbits reacted with H2A in ELISA, whereas the
antisera to peptide T2 did not (Fig. 3).
ReactivityofAntisera to Peptides TIand T2in ImmunoblottingExperiments.
￿
Theability
ofthe peptide antisera to react with the different components found to be present
incommercial ubiquitin preparations (3)was tested by immunoblotting. When ubiq-
uitin was analyzed by PAGE, immunostaining with antiubiquitin antibodies revealed
the expected Mr 8.7 band as well as the P43 and P52 components (Fig. 4, lanes
7-10); the latter two components were also revealed with antiTl and antiT2 anti-
bodies (Fig. 4, lanes 16 and 17), anti-H2A and anti-H2B antibodies (lanes 11 and
12), and by a majority ofSLE sera (lanes 3-6). Because ofthe sequence homology
offive residues in the branched domain, it is possible that anti-T2 antibodies recog-
nize both U-H2A and U-H2B. Anti-T2 antibodies, as well as anti-TI antibodies,
FIGURE 3.
￿
Bindingin ELISAofubiq-
uitin (A) and histone H2A (B) to an-
tisera against peptides TI (V) and T2
(p), H2A(0), and KLH-conjugated
ubiquitin (/). Absorbance values were
measured after substrate hydrolysis
time of 60 min.PLAUE ET AL .
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FIGURE 4 .
￿
Immunoblotting of components present in ubiquitin preparations revealed with an-
tisera directed against ubiquitin, peptide 22-45 ofubiquitin, peptides TI andT2,and individual
histones, as well as with SLE sera . Ubiquitin (10 hg/cm) was resolved inSDS 12-20% polyacryl-
amide gel (lane 1, Coomassie staining) and electrophoretically transferred on hydrophobic Im-
mobilon membrane (lane 2, blot stained with amino black 0.1% in the mixture methanol-acetic
acid-water 9:9:2 vol/vol/vol) . For immunoblotting, all sera were diluted 1 :1,000 in PBS= Sera
were as follows: lanes 3-6, SLE sera; lane 7, anti-KLH ubiquitin conjugate; lane 8, antipeptide
CYS 22-45 ; lane 9, antipeptide 22-45 ; lane 10, antipeptide 22-45 coupled to OVA ; lane 11,
anti-H2A ; lane 12, anti-11213 ; lane 13, anti-113 ; lane 14, anti-114; lane 15, anti-Hl; lane 16,
antipeptide Tl ; lane 17, antipeptide T2 . After incubation with sera and 1251-protein A, immu-
noblots were revealed by autoradiography at -70°C with an intensifying screen .
did not react in immunoblotting (serum dilution 1 :100) with pure 112A and H2B
or with other individual histones, H3, H4, and111 (datanot shown) . Thus, the results
obtained with anti-TI and antiT2 antibodies confirm the previous finding that the
P52 and P43 polypeptides correspond to covalent conjugates ofU-H2A and/orU-H2B .
Binding in ELISA ofAutoantibodiesfrom SLE Patients to Peptides TI and T2 ofU-MA .
From the results presented above, it clearly appears that P52 and P43 containing
U-142A (U-MB) exhibit a stronger reactivity with SLE sera than does ubiquitin
itself. Therefore, in order to know whether autoimmune sera contained autoanti-
bodies with a narrow specificity for U-MA, we examined a number of patients'
sera for the presence of antibodies able to react in ELISA with the branched pep-
tides T2 and T1 ofU-MA . The threshold for considering a serum positive was an
arbitrary cut-off line corresponding to 0.3OD units (3) . As shown in Table I, 96%
of the SLE sera (diluted 1 :500) that recognized ubiquitin and DNA also reacted
with peptide T2 . In the case of SLE sera that reacted with ubiquitin but not with
native DNA, the frequency of anti-T2 antibodies was slightly less (85%), although
it remained high . On the other hand, only 13% ofSLE sera that did not reactwith
ubiquitin possessed antibodies able to bind peptide T2 . The reactivity ofthe different
sera with peptides Tl and T2 was very similar (data not shown) . Among the SLE
study group, 51.8% of sera contained autoantibodies to H2A; 62.1% of these sera
also reacted with T2 and 17.9% did not . In the group of sera negative with H2A,
53.8% of sera reacted with T2 and 46.1% did not. Experiments are currently in
progress to analyze with T2 a larger population ofSLE sera with respect to anti-T2
activity in an attempt to correlate the presence of such antibodies with particular
clinical features .1612
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TABLE I
Incidence ofAutoantibodies Reacting in ELISA with Peptide T2 of U-112A
in Sera of Patients with Rheumatic Disease
The sera were considered positive when' OD values were >0.3 after 1 h incubation of anti-human Ig en-
zyme conjugate with substrate.
' Reactivity with native DNA and ubiquitin was measured as described previously (3) except that all sera
were diluted 1:500.
Values represent OD units measured with T2 peptide, using patients' sera diluted 1 :500 .
5 Upper limit ;~ 2.0 OD units.
Since in a previous study weobservedthat 16% of43 sera from patientswith rheu-
matoid arthritis (RA) and 15% of 48 patients with scleroderma reacted with ubiq-
uitin (3), the reactivity ofthese sera with peptides TI and T2 was also analyzed by
ELISA. In contrast to SLE sera, none of the RA sera that reacted with ubiquitin
or with peptide 22-45 of ubiquitin contained antibodies able to bind peptides Tl
and T2 (Table I). In the case ofscleroderma patients, two ofsix sera possessed au-
toantibodiesspecific forubiquitinand peptideT2. Control experimentsshowed that
rabbit antisera to ubiquitin and to H2A did not bind in ELISA with peptides TI
and T2.
Affinity Chromatography Purification and Characterization ofAntiT2 Autoantibodies.
￿
To
establish ifit was the same population ofautoantibodies in SLE sera that recognize
both theP43 and P52 components and the ubiquitin andhistone molecules, affinity
columns were prepared with the T2 peptide. When thiol Sepharose 4B was used
to immobilize peptide T2 through its additional cysteine, no detectable antibodies
recognizing T2 in ELISA were found to be present in SLE sera and were retained
on the T2-adsorbent column. In contrastwith this result, control rabbit antiT2 anti-
bodies reacted with the T2 adsorbent inthese conditions and were eluted with0.2 M
glycine, pH 3, as expected.
Another immunoadsorbent was prepared by coupling peptideT2 to Act-Ultrogel
AcA 22 support. Inthiscase, antibodies from the seven different SLE serathat were
tested were specifically bound(examples are shown in Fig. 5) and subsequently eluted
at pH 3. The purified antibody fractions were found to recognize peptide T2 in
ELISA, and depending on the particular SLE serum, the antibodies also bound in
ELISA to H2A, and in three cases out ofseven, also to ubiquitin (Fig. 5). In com-
parison, rabbit anti-T2 antibodies specifically eluted from the column reacted with
T2 but not with isolated ubiquitin and H2A.
Type of sera Known antigen reactivity'
Number
of sera
Frequency of
binding to T2
peptide OD range ODt
SLE DNA + ; ubiquitin + 26 96 (0.3;2 .00)5 -
DNA - ; ubiquitin + 13 85 (0.3;1 .52) 0.69
DNA + ; ubiquitin - 15 13 (0.3;0 .32) 0.31
RA Ubiquitin + 7 0
Ubiquitin - 14 0
Scleroderma Ubiquitin + 6 33 (0.3;0 .62) 0.50
Ubiquitin - 5 0 - -c 15
h
3
c
O
1.0
QS
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FIGURE 5.
￿
Affinity chromatography
ofSLEsera on T2 peptide conjugated
to Act-Ultrogel AcA22; 500 Al un-
diluted SLE serumwas loaded onto a
5 x 1.3-cm column equilibrated in 10
mM PBS, pH 7.5. After 3 h incuba-
tion at room temperature, elutionwith
thesame buffer was used to wash un-
boundmaterial. Fractionsof2 ml were
collected. Antibodies were eluted with
0.2 Mglycine, pH 3.0 (arrow). Thefrac-
tions (0.5 ml) were immediately neu-
tralized with 0.1 M Tris, pH 8.8 (vol/
vol). The eluted fractions were tested
after dilution 1:2 in PBSTBSA. (A)
Fractionationprofiles of twoSLE sera
(", ")tested in ELISAwith 2 AM T2
as solid phase antigen. (B) Fraction-
ation profile of a third SLE serum
tested in ELISA with T2 (A), H2A
(A), or ubiquitin(O)as antigens. Ab-
sorbance values were measured after
hydrolysis time of 60 min.
Discussion
Autoantibodies to a wide variety of cellular constituents have been reported in
different rheumatic diseases (28). In SLE sera, antiubiquitin antibodies have been
identified by immunoblotting and by ELISA using ubiquitin and a synthetic pep-
tide ofubiquitin(residues 22-45), as solid phase antigens (3). SLE sera also reacted
in immunoblotting with ubiquitinated H2A and H2B complexes of apparent Mr
43 and 52 kD. In the present paper, these conjugates were further studied by means
of antibodies directed against a synthetic peptide corresponding to a branched re-
gion of U-H2A. In view of the unusual structure of the branched peptide T2, it
seemed possible that antibodies raised against it would constitute a specific probe
forU-1-12A unable to bind to either ubiquitinor H2A alone. Antibodies raised against
the T2 octapeptide of U-H2A were found to react with the P43 and P52 compo-
nents. It is noteworthy that when two additional amino acid residues located in the
H2A sequence were present as in peptide T1, the antibodies elicited by this longer
peptide did recognize H2A in ELISA (although not in immunoblotting). The use
of antibodies raised against a synthetic peptide corresponding to a covalent-linked
region betweentwo individual proteins makes it possible to identify such conjugates
unequivocally. This type ofantibody probe should thus be useful for analyzing such
complexes that at present are difficult to study in vitro and in vivo. Experiments
are currentlyin progress in ourlaboratory to identify the presence of ubiquitinated
histone complexes in different types of cellular extracts.
Theexistence ofubiquitinated histone specieshasbeen reported (29, 30). Although
some of these molecules were found to accumulate in decondensed, possibly tran-
scribed chromatin regions, the precise role of theseconjugates has not yet been elu-
cidated. One possibility is that polyubiquitination of H2A and H2B may function
in tagginghistones for degradation. Alternatively, ubiquitinated conjugates P53 and
P42 may be related to ubiquitin-labeled forms of labile H2A-H2B dimers displaced1614
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from nucleosomes in "active" genes (16, 31, 32). In native chromatin fibers, the two
respective primary branching points in H2A and H2B have been found to be ex-
posed for ubiquitination (33, Hacques, M. F., S. Muller, and C. Marion, manu-
script submitted for publication).
Despite intensive efforts, no etiology has yet been found for SLE. Very probably,
the development of SLE is multifactorial and requires contact with a pathogen or
other factors, together with a particular predisposition of the host. In the present
paper, we confirm that SLE patients possess autoantibodies able to bind ubiquiti-
nated histone species. The specificity of the antibodies was clearly established by
using branched peptides of U-H2A. The precise delineation of the region recog-
nized by autoantibodies by means of the octapeptide T2 corroborate the presump-
tive evidence that U-H2A may play a role in the SLE autoimmune response (3).
Interestingly, the specificity of antiubiquitin autoantibodies found in SLE, RA, and
scleroderma appears to be different with regard to their reactivity with peptide T2.
This implies that different mechanisms maybe involved in the inductionof antiubiq-
uitin autoantibodies in these rheumatic diseases and that additional ubiquitinated
conjugates may be implicated.
As far as the specificity of autoantibodies to U-H2A is concerned, ourresults show
that some of the antibodies affinity purified on T2 adsorbent still react with H2A.
Although a larger systematic survey of patient sera would be required to establish
the generality ofthis phenomenon, ourresults suggestthat it is possible forautoanti-
bodies directed to U-H2A to be classified as "anti-H2," antibodies as a result of
their reactivity with isolated H2A in ELISA. Since the same could be true for other
antibodies directed to various ubiquitinated receptor proteins, the development of
improved diagnostic tests forautoimmune diseasemay require fine specificity studies
at the epitope level.
The data presented here agree with the hypothesis of an antigen-driven immune
response where the"autoantigen" could represent subcellular particlesor amulticom-
ponent molecular assembly rather than isolated proteins of the nucleus, nucleolus,
or cytoplasm (34) . Since ubiquitin is particularly abundant in the cell and appears
to be a multifunctional protein affecting chromatin structure, intracellular proteol-
ysis, cellular interactions, andthe stress response, it is tempting to link this molecule
with various manifestations of the autoimmune response. The mechanism through
which histoneubiquitination could be involved in SLE remains unknown. It is con-
ceivable that transient ubiquitin binding to self components could break tolerance
and lead to autoimmunity either by modifying the receptor proteins themselves or
by altering their interactions with othercellular components. It is also possible that
in certain susceptible individuals, a strong immune response to ubiquitinated his-
tonesoccurs when the DNA repair system becomesstrongly stimulated. Otherpost-
translational modifications of proteins have also been described as possible medi-
ators for autoimmune response. These include phosphorylation (35), poly (ADP
ribosyl)ation (36), and defective glycosylation of IgG in rheumatoid arthritis (37).
All these findings are in agreement with the hypothesis that transitorily modified
cellular components play a triggering role in autoimmune disorders.
Summary
Two peptides of eight (T2) and 10 (T1) residues corresponding to the branched
moiety of ubiquitinated histone H2A have been synthesized and used for raisingspecific antibodies in rabbits. Antisera to peptide T1 reacted in ELISA with TI and
with H2A but not with ubiquitin; antisera to peptide T2 reacted with T2 but not
with H2Aor ubiquitin. When tested in immunoblotting, both peptide antisera reacted
with ubiquitinated H2A but not with unconjugated H2A or with ubiquitin.
Sera from patients with systemic lupus erythematosus (SLE) were shown previ-
ously to react with ubiquitin in ELISA and immunoblotting. When tested fortheir
ability to react in ELISA with synthetic peptides TI and T2, 96%v of the SLE sera
(diluted 1 :500) that recognized ubiquitin also reacted with peptide T2. Ofthe SLE
sera that did not react with ubiquitin, only 13 % possessed antibodies able to bind
peptide T2 . Antibodies from seven SLE sera, purified on a T2-immunoadsorbent
column, were also able to reacteither with H2A, and in three cases also with ubiquitin.
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